Our Take
A first CRO hire is defensive positioning, not offensive strategy—Insulet is responding to competitive pressure, not announcing a capability breakthrough.
Why it matters
Insulet dominates the tubeless insulin-pump market, but competitors are closing in. Formalizing R&D leadership suggests the company believes it needs structural changes to sustain that lead.
Do this week
Insulet customers: monitor product roadmap announcements over the next 18 months to assess whether this hire translates to clinically meaningful improvements in accuracy, battery life, or ease of use.
Insulet Names Its First Chief R&D Officer
Insulet Corporation appointed Divakar Ramakrishnan as chief R&D officer, the company announced this week. Ramakrishnan joins from Convatec, where he held an R&D leadership role. He also spent time at Eli Lilly, a major pharmaceutical employer with substantial medical-device operations.
The position is new for Insulet. The company said the hire reflects efforts to strengthen innovation capabilities amid what it framed as a competitive landscape shift in the insulin-pump market.
Insulet Is Playing Catch-Up, Not Running Ahead
Insulet owns roughly 80% of the U.S. tubeless insulin-pump market (company-reported figures). That dominance makes the hire notable not because it signals new territory, but because it signals Insulet felt obligated to defend existing ground.
The hire pattern matters. When market leaders hire their first chief R&D officer after years of operation, it usually means one of two things: the company has grown large enough to need formal R&D governance, or competitors have begun stealing market share and the old structure isn't moving fast enough. Given Insulet's size and age, the second explanation is more likely.
Ramakrishnan's background at Eli Lilly (a company with strong insulin-pump and continuous-glucose-monitor partnerships) and Convatec (a major player in ostomy and continence care) suggests Insulet is hunting for experience in scaling device innovation and managing complex supply chains. Neither signal suggests a fundamental shift in pump technology on the horizon.
What to Watch
Insulet's Omnipod system remains the market standard for ease of use and discrete wear. A new CRO will not instantly change that. But it may accelerate incremental improvements in battery life, app responsiveness, and integrations with continuous-glucose monitors.
If you're a healthcare provider or a patient evaluating pump options, expect more frequent feature updates and faster iterative cycles over the next 12 to 24 months. If you're a competing pump maker, this hire confirms Insulet is willing to invest to stay ahead—a signal to match or exceed that R&D spending or cede ground further.